AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16218969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-oral injection of ketorolac (30 mg in 1 mL)
Number of subjects: 10
Study 16218969 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 mL)
Number of subjects: 10
Study 16218969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 10
Study 11872034 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine SL (2 mg for 2 weeks, then 3 mg for 2 weeks, and finally 4 mg for the remaining 4 weeks)
Number of subjects: 507
Study 11872034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 11872034 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine SL
Number of subjects: 507
Study 9989366 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg od)
Number of subjects: 20
Study 7787438 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive antithyroid drugs (ATD) in a form of block‐replacement regimen of methimazole (MMI) plus L‐T4 for 6 months
Number of subjects: 159
Study 7787438 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine (RAI) therapy alone
Number of subjects: 159
Study 2370643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (acute and chronic treatment)
Number of subjects: 18
Study 6966329 — intervention group
Group type: EXPERIMENTAL
Intervention: Real stimulation
Number of subjects: 8
Study 6966329 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study 31991296 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (1500 mg, three times per day) for 3 months
Number of subjects: 72
Study 31991296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 29906580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic hybrid instrumentation (Dynesys‐Transition‐Optima)
Number of subjects: 30
Study 29906580 — intervention group
Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 30
Study 29906580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PLIF and Dynesys)
Number of subjects: 30
Study 27096854 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa oleifera leaves extract (200mg/kg/day)
Number of subjects: 20
Study 27096854 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 20
Study 24720268 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile anaesthesia
Number of subjects: 154
Study 24720268 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthesia
Number of subjects: 154
Study 24720268 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study 22975864 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS applied over the right dorsolateral prefrontal cortex
Number of subjects: 10
Study 22975864 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 10
Study 22975864 — intervention group
Group type: COMPARATOR
Intervention: Active rTMS applied over the left dorsolateral prefrontal cortex
Number of subjects: 10
Study 19923361 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (3 months)
Number of subjects: 12
Study 19923361 — intervention group
Group type: COMPARATOR
Intervention: Control (no training, n = 5)
Number of subjects: 12
Study 19923361 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running training (5 weeks in mice)
Number of subjects: 12
Study 17081532 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative triptorelin treatment
Number of subjects: 100
Study 16251373 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (weekly exercise class consisting of light aerobic exercise, muscle strengthening and stretching for 6 months)
Number of subjects: 129
Study 16251373 — intervention group
Group type: COMPARATOR
Intervention: Control (ordinary activity)
Number of subjects: 129
Study 16251373 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 129
Study 16251373 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise and Control
Number of subjects: 129
Study 12126173 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnets
Number of subjects: 43
Study 12126173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 10341016 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN 10 mg/day
Number of subjects: 246
Study 8734558 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery focused on increasing neutrophil adherence
Number of subjects: 15
Study 8734558 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery focused on decreasing neutrophil adherence
Number of subjects: 15
Study 8734558 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting sessions without imagery training)
Number of subjects: 15
Study 1918559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CT)
Number of subjects: 60
Study 1918559 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral marital therapy (BMT)
Number of subjects: 60
Study 1918559 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (CO)
Number of subjects: 60
Study 6621852 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (various doses)
Number of subjects: 0
Study 6621852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6621852 — intervention group
Group type: EXPERIMENTAL
Intervention: Methscopolamine
Number of subjects: 0
Study 31447237 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced-guided liver biopsy (CEUSLB)
Number of subjects: 144
Study 31447237 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided liver biopsy (USLB)
Number of subjects: 144
Study 30087294 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint essential oil (100 µl)
Number of subjects: 24
Study 30087294 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint essential oil (50 µl and 100 µl)
Number of subjects: 24
Study 30087294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26584339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (n=605)
Number of subjects: 1184
Study 26584339 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n=579)
Number of subjects: 1184
Study 26584339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 1184
Study 26584339 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity worse than 20/100
Number of subjects: 1184
Study 25800041 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intra-arterial chemotherapy (IAC) and concomitant radiotherapy (RT)
Number of subjects: 120
Study 25800041 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 120
Study 22492368 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL red orange juice/d
Number of subjects: 19
Study 22492368 — intervention group
Group type: COMPARATOR
Intervention: 500 mL placebo/d
Number of subjects: 19
Study 20646715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 5% saline
Number of subjects: 165
Study 20646715 — intervention group
Group type: COMPARATOR
Intervention: Nebulized 0.9% saline (normal saline)
Number of subjects: 165
Study 20646715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 3% saline
Number of subjects: 165
Study 20646715 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 165
Study 19227904 — intervention group
Group type: EXPERIMENTAL
Intervention: teraflex for 3 months
Number of subjects: 80
Study 15943578 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced meal (50% carbohydrates, 30% fat, 20% protein)
Number of subjects: 11
Study 15943578 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal (45% carbohydrates, 20% fat, 35% protein)
Number of subjects: 11
Study 15943578 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal (45% carbohydrates, 45% fat, 10% protein)
Number of subjects: 11
Study 11815408 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 11815408 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0
Study 11815408 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10037082 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 (8 microg/kg birth weight per day)
Number of subjects: 200
Study 10037082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 7719564 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based eligibility screening system
Number of subjects: 60
Study 2039045 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative 0.03% flurbiprofen every 30 minutes for four doses
Number of subjects: 30
Study 2039045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6981162 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of two double-strength trimethoprim-sulfamethoxazole (TMP-SMZ) tablets (320 mg of TMP and 1,600 mg of SMZ)
Number of subjects: 104
Study 6981162 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy of one double-strength tablet (160 mg of TMP and 800 mg of SMZ) twice a day for 10 days
Number of subjects: 104
Study 6981162 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose therapy
Number of subjects: 104
Study 6981162 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 104
Study 30801436 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training Group (ETG)
Number of subjects: 30
Study 30801436 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study 28686776 — intervention group
Group type: EXPERIMENTAL
Intervention: A/BPO gel 0.3%/2.5%
Number of subjects: 217
Study 28686776 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 217
Study 26329939 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tacrolimus 0.03% twice daily for three weeks
Number of subjects: 60
Study 26329939 — intervention group
Group type: COMPARATOR
Intervention: 1% Hydrocortisone acetate for three weeks
Number of subjects: 60
Study 24862764 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming (Wii Fit training)
Number of subjects: 30
Study 24862764 — intervention group
Group type: COMPARATOR
Intervention: Conventional weight-shift training (Control)
Number of subjects: 30
Study 24862764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Exergaming and Control)
Number of subjects: 30
Study 21658805 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sucralfate
Number of subjects: 80
Study 21658805 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 19755144 — intervention group
Group type: EXPERIMENTAL
Intervention: GMZ2 (10, 30, and 100 microg)
Number of subjects: 30
Study 17313301 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g L-carnitine L-tartrate
Number of subjects: 8
Study 17313301 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g L-carnitine L-tartrate
Number of subjects: 8
Study 17313301 — intervention group
Group type: COMPARATOR
Intervention: 0 g L-carnitine L-tartrate (control)
Number of subjects: 8
Study 17055209 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar (200 mg levodopa and 50 mg benserazide)
Number of subjects: 12
Study 17055209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15687727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole (injection) 40 mg once daily for 1 week, followed by oral esomeprazole 40 mg once daily for 3 weeks
Number of subjects: 100
Study 15687727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole (infusion) 40 mg once daily for 1 week, followed by oral esomeprazole 40 mg once daily for 3 weeks
Number of subjects: 100
Study 15687727 — intervention group
Group type: COMPARATOR
Intervention: Oral esomeprazole 40 mg once daily for 4 weeks
Number of subjects: 100
Study 11218319 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care (intervention)
Number of subjects: 479
Study 9179508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (10-40% concentration)
Number of subjects: 19
Study 8233728 — intervention group
Group type: EXPERIMENTAL
Intervention: High caloric supplement (500 kcal/d)
Number of subjects: 0
Study 8233728 — intervention group
Group type: COMPARATOR
Intervention: Low caloric supplement (140 kcal/d)
Number of subjects: 0
Study 3898976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin 700 mg twice daily for 6 days
Number of subjects: 86
Study 3898976 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 400 mg three times daily for 7 days
Number of subjects: 86
Study 31476994 — intervention group
Group type: EXPERIMENTAL
Intervention: App-controlled feedback devices (BIA scale, blood pressure monitor, step counter)
Number of subjects: 89
Study 31476994 — intervention group
Group type: COMPARATOR
Intervention: Mechanical pedometer without app
Number of subjects: 89
Study 27779777 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus text-only behaviour change technique-based intervention
Number of subjects: 177
Study 27779777 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus text + visual behaviour change technique-based intervention
Number of subjects: 177
Study 27779777 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 177
Study 25794603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dabrafenib and trametinib
Number of subjects: 0
Study 25794603 — intervention group
Group type: COMPARATOR
Intervention: Dabrafenib monotherapy
Number of subjects: 0
Study 23829035 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic ports
Number of subjects: 0
Study 23829035 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS devices
Number of subjects: 0
Study 21497843 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 66
Study 21497843 — intervention group
Group type: COMPARATOR
Intervention: Pelvic organ prolapse repair alone
Number of subjects: 66
Study 18783414 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain fused to TiAdapt titanium abutments (test)
Number of subjects: 35
Study 18783414 — intervention group
Group type: COMPARATOR
Intervention: Cement crowns onto CeraOne abutments (control)
Number of subjects: 35
Study 16317803 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 0
Study 16317803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15226337 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated cranial radiation therapy (CFX)
Number of subjects: 369
Study 15226337 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated cranial radiation therapy (HFX)
Number of subjects: 369
Study 11477497 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2 g CLA/day
Number of subjects: 25
Study 11477497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10437461 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 22
Study 10437461 — intervention group
Group type: COMPARATOR
Intervention: Knowledge-supplied intervention
Number of subjects: 22
Study 7822600 — intervention group
Group type: COMPARATOR
Intervention: Routine oral thermometry (CRAFTEMP)
Number of subjects: 275
Study 7822600 — intervention group
Group type: COMPARATOR
Intervention: Optimum oral thermometry (TERUMO WCT)
Number of subjects: 275
Study 7822600 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine rectal thermometry (TERUMO WCT)
Number of subjects: 275
Study 7822600 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum rectal thermometry (TERUMO WCT)
Number of subjects: 275
Study 3168766 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg dexamethasone
Number of subjects: 50
Study 3168766 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abstinence
Number of subjects: 50
Study 3168766 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal DST response
Number of subjects: 50
Study 3168766 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic status
Number of subjects: 50
Study 30938764 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 37
Study 30938764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 30938764 — intervention group
Group type: EXPERIMENTAL
Intervention: Not assessable
Number of subjects: 37
Study 28329124 — intervention group
Group type: EXPERIMENTAL
Intervention: Interns working extended overnight shifts
Number of subjects: 224
Study 28329124 — intervention group
Group type: COMPARATOR
Intervention: Residents not working overnight shifts
Number of subjects: 224
Study 28329124 — intervention group
Group type: EXPERIMENTAL
Intervention: Interns on on-call nights
Number of subjects: 224
Study 28329124 — intervention group
Group type: EXPERIMENTAL
Intervention: Interns after on-call nights
Number of subjects: 224
Study 28329124 — intervention group
Group type: EXPERIMENTAL
Intervention: Interns post-call naps
Number of subjects: 224
Study 25705889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal fluticasone propionate
Number of subjects: 48
Study 25705889 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 48
Study 23305402 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard AVSH
Number of subjects: 81
Study 23305402 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced AVSH
Number of subjects: 81
Study 23305402 — intervention group
Group type: COMPARATOR
Intervention: Fixed atrioventricular delay
Number of subjects: 81
Study 21424338 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIM-Diabetes (TRIM-D)
Number of subjects: 0
Study 21424338 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIM-Diabetes Device (TRIM-DD)
Number of subjects: 0
Study 21424338 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIM-D and TRIM-DD
Number of subjects: 0
Study 21424338 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement model
Number of subjects: 0
Study 21424338 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal consistency of TRIMs
Number of subjects: 0
Study 18071344 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit-based intervention (n=69, with subgroups of n=33 for weekly weighing and n=36 for monthly weighing)
Number of subjects: 104
Study 18071344 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit-based intervention (n=69)
Number of subjects: 104
Study 18071344 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (n=35)
Number of subjects: 104
Study 16421649 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about deepest thoughts and feelings about living with HIV
Number of subjects: 79
Study 16421649 — intervention group
Group type: COMPARATOR
Intervention: Control group writing about activities in the last 24 hours
Number of subjects: 79
Study 10937312 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep loss participants (29-50 hr)
Number of subjects: 93
Study 10937312 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 45)
Number of subjects: 93
Study 9346982 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine-adrenaline-cocaine (TAC)
Number of subjects: 240
Study 9346982 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine-phenylephrine
Number of subjects: 240
Study 9346982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine-lidocaine-phenylephrine
Number of subjects: 240
Study 9346982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraphen
Number of subjects: 240
Study 9346982 — intervention group
Group type: EXPERIMENTAL
Intervention: Three new topical anesthetics (prilocaine-phenylephrine, tetracaine-phenylephrine, tetracaine-lidocaine-phenylephrine)
Number of subjects: 240
Study 8478305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin (500 mg orally once daily)
Number of subjects: 1222
Study 8478305 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (250 mg orally qds)
Number of subjects: 1222
Study 3006464 — intervention group
Group type: EXPERIMENTAL
Intervention: diatrizoate (ionic radiographic contrast agent)
Number of subjects: 46
Study 3006464 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol (nonionic radiographic contrast agent)
Number of subjects: 46
Study 30518693 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg) + Saline
Number of subjects: 12
Study 30518693 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg)
Number of subjects: 12
Study 30518693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo Metformin
Number of subjects: 12
Study 30518693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26343026 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-Free/Casein-Free (GFCF) diet
Number of subjects: 14
Study 26343026 — intervention group
Group type: COMPARATOR
Intervention: Dietary challenges (gluten, casein, gluten and casein, or placebo)
Number of subjects: 14
Study 25562774 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention (usual care plus pharmaceutical care)
Number of subjects: 200
Study 25562774 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 200
Study 22987572 — intervention group
Group type: COMPARATOR
Intervention: 5 mg rosuvastatin
Number of subjects: 87
Study 22987572 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin
Number of subjects: 87
Study 20932368 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar fitted with a spiral thread on the sleeve (Group A)
Number of subjects: 131
Study 20932368 — intervention group
Group type: COMPARATOR
Intervention: Trocar with plain sleeve (Group B)
Number of subjects: 131
Study 20932368 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar with plain sleeve + fixator (Group C)
Number of subjects: 131
Study 18236371 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506 eye drops 3 x /day for six months
Number of subjects: 40
Study 18236371 — intervention group
Group type: COMPARATOR
Intervention: prednisolone acetate 1 % eye drops 5 x /day, tapering off by one drop every month
Number of subjects: 40
Study 16487668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prison methadone treatment
Number of subjects: 0